atai Life Sciences (ATAI) Competitors $3.58 -0.17 (-4.41%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATAI vs. INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, and HRMYShould you be buying atai Life Sciences stock or one of its competitors? The main competitors of atai Life Sciences include Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. atai Life Sciences vs. Its Competitors Indivior Recursion Pharmaceuticals Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences atai Life Sciences (NASDAQ:ATAI) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Which has more volatility & risk, ATAI or INDV? atai Life Sciences has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ATAI or INDV? 28.4% of atai Life Sciences shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 26.8% of atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to ATAI or INDV? In the previous week, Indivior had 5 more articles in the media than atai Life Sciences. MarketBeat recorded 7 mentions for Indivior and 2 mentions for atai Life Sciences. atai Life Sciences' average media sentiment score of 1.17 beat Indivior's score of 0.41 indicating that atai Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment atai Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ATAI or INDV more profitable? atai Life Sciences has a net margin of 0.00% compared to Indivior's net margin of -4.02%. Indivior's return on equity of -97.29% beat atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets atai Life SciencesN/A -102.10% -77.55% Indivior -4.02%-97.29%15.74% Do analysts rate ATAI or INDV? atai Life Sciences presently has a consensus price target of $9.00, indicating a potential upside of 151.75%. Indivior has a consensus price target of $17.75, indicating a potential upside of 4.25%. Given atai Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe atai Life Sciences is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Indivior 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has higher earnings and valuation, ATAI or INDV? Indivior has higher revenue and earnings than atai Life Sciences. Indivior is trading at a lower price-to-earnings ratio than atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioatai Life Sciences$310K2,310.37-$149.27M-$0.91-3.93Indivior$1.19BN/A$2M-$0.31-54.92 Summaryatai Life Sciences and Indivior tied by winning 8 of the 16 factors compared between the two stocks. Get atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricatai Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$718.22M$3.78B$5.72B$9.52BDividend YieldN/A1.33%4.60%3.99%P/E Ratio-3.9432.7128.0720.02Price / Sales2,310.37130.06462.58104.32Price / CashN/A22.4036.5558.97Price / Book5.184.398.645.90Net Income-$149.27M$189.47M$3.24B$258.50M7 Day Performance10.68%2.03%4.08%2.12%1 Month Performance62.50%-3.43%10.68%12.62%1 Year Performance126.27%-2.50%34.47%19.25% atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIatai Life Sciences3.437 of 5 stars$3.58-4.4%$9.00+151.7%+147.7%$718.22M$310K-3.9480Gap UpINDVIndivior1.1562 of 5 stars$15.62+0.9%$17.00+8.9%+54.5%$2.15B$1.17B-50.371,051News CoverageAnalyst ForecastRXRXRecursion Pharmaceuticals1.4367 of 5 stars$5.27-0.3%$7.00+33.0%-19.8%$2.14B$59.82M-2.97400DNLIDenali Therapeutics4.2552 of 5 stars$14.68+1.1%$33.71+129.7%-39.4%$2.13B$330.53M-5.50430News CoveragePositive NewsUpcoming EarningsBEAMBeam Therapeutics2.2175 of 5 stars$21.17+0.0%$48.75+130.3%-29.7%$2.13B$63.52M-4.59510Analyst RevisionKNSAKiniksa Pharmaceuticals International3.4535 of 5 stars$28.81+2.6%$39.33+36.5%+6.7%$2.10B$423.24M-115.26220News CoverageBLTEBelite Bio1.7942 of 5 stars$63.55+0.5%$96.67+52.1%+28.5%$2.02BN/A-46.7310High Trading VolumeCNTACentessa Pharmaceuticals3.3153 of 5 stars$15.05+4.3%$27.89+85.3%+51.2%$2.01B$15M-8.31200High Trading VolumeVCELVericel3.6702 of 5 stars$39.89-0.1%$61.14+53.3%-24.2%$2.01B$238.54M1,329.98300News CoveragePositive NewsUpcoming EarningsIRONDisc Medicine3.3594 of 5 stars$57.82+1.6%$96.70+67.2%+36.0%$2.00BN/A-14.7530Gap UpHRMYHarmony Biosciences4.7974 of 5 stars$34.71+2.1%$51.33+47.9%+11.9%$1.99B$714.73M13.25200Positive NewsAnalyst Revision Related Companies and Tools Related Companies INDV Competitors RXRX Competitors DNLI Competitors BEAM Competitors KNSA Competitors BLTE Competitors CNTA Competitors VCEL Competitors IRON Competitors HRMY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATAI) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding atai Life Sciences N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATAI Stock Alerts